Who Exports Terbinafine from India — 292 Suppliers Behind a $27.4M Market
India's terbinafine export market is supplied by 292 active exporters who collectively shipped $27.4M across 3,118 shipments. AUROBINDO PHARMA LTD leads with a 37.3% market share, followed by AUROBINDO PHARMA LIMITED and BAFNA PHARMACEUTICALS LIMITED. The top 5 suppliers together control 65.8% of total export value, reflecting a concentrated market structure.
Top Terbinafine Exporters from India — Ranked by Export Value
AUROBINDO PHARMA LTD is the leading terbinafine exporter from India, holding a 37.3% share of the $27.4M market across 3,118 shipments from 292 exporters. The top 5 suppliers — AUROBINDO PHARMA LTD, AUROBINDO PHARMA LIMITED, BAFNA PHARMACEUTICALS LIMITED, MANKIND PHARMA LIMITED, CIPLA LIMITED — collectively control 65.8% of total export value, indicating a moderately concentrated market. Individual shares are: AUROBINDO PHARMA LTD (37.3%), AUROBINDO PHARMA LIMITED (8.9%), BAFNA PHARMACEUTICALS LIMITED (7.5%), MANKIND PHARMA LIMITED (7.2%), CIPLA LIMITED (4.9%).
Top Terbinafine Exporters from India
Ranked by export value · 292 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | AUROBINDO PHARMA LTD TERBINAFINE TABLETS 250MG 30'STERBINAFINE TABLETS USP 250MGTERBINAFINE TABLETS 250MG (TERBINAFINE A | $10.2M | 11 | 37.3% |
| 2 | AUROBINDO PHARMA LIMITED TERBINAFINE TABLETS 250MG 30'STERBINAFINE TABLETS USP 250MGTERBINAFINE TABLETS 250MG (TERBINAFINE A | $2.4M | 8 | 8.9% |
| 3 | BAFNA PHARMACEUTICALS LIMITED TABISAFE TABLETS 250MG (TERBINAFINE TABLTABISAFE TABLETS USP 250MG (TERBINAFINETERBINAFINE 250MG TABLETS (ETHINAFINE 25 | $2.1M | 1 | 7.5% |
| 4 | MANKIND PHARMA LIMITED TERBINAFINE TABLETS 250MG 30'STERBINAFINE TABLETS USP 250MGTERBINAFINE TABLETS 250MG 30S | $2.0M | 10 | 7.2% |
| 5 | CIPLA LIMITED TERBINAFINE HYDROCHLORIDE 250MG TABLET(1TERBINAFINE TABLETS 250MG 100'STERBINAFINE TABLETS 250MG(AURO-TERBINAFI | $1.3M | 7 | 4.9% |
| 6 | IND SWIFT LIMITED TERBINAFINE TABLETS 250MG 30'STABISAFE TABLETS 250MG (TERBINAFINE TABLTABISAFE TABLETS USP 250MG (TERBINAFINE | $1.2M | 7 | 4.2% |
| 7 | ORBION PHARMACEUTICALS PRIVATE LIMITED TERBINAFINE TABLETS 250MG 30'STERBINAFINE TABLETS USP 250MGTERBINAFINE TABLETS 250MG 30S | $1.1M | 1 | 4.1% |
| 8 | MEDREICH LIMITED TABISAFE TABLETS 250MG (TERBINAFINE TABLTABISAFE TABLETS USP 250MG (TERBINAFINETERBINAFINE 250 MG TABLETSBL (TER | $865.1K | 2 | 3.2% |
| 9 | UNISON PHARMACEUTICALS PRIVATE LIMITED TERBINAFINE 250 MG TABLETSBL (TERTERBINAFINE 250MG TABLETSTERBINAFINE 250MG TABLETS- 1302150-PACKSIZE -QTY-68860 | $632.6K | 1 | 2.3% |
| 10 | MARKSANS PHARMA LIMITED TERBINAFINE 250 MG TABLETSBL (TERTERBINAFINE 250MG TABLETSTERBINAFINE 250MG TABLETS- 1302150-PACKSIZE -QTY-68860 | $596.9K | 2 | 2.2% |
| 11 | AGIO PHARMACEUTICALS LIMITED TERBINAFORCE CREAM 15G TUBE TERBINAFINE | $512.1K | 3 | 1.9% |
| 12 | INTAS PHARMACEUTICALS LIMITED TERBINAFINE 250 MG TABLETSBL (TERTERBINAFINA VIATRIS 250 MGTERBINAFINE 250MG TABLETS | $274.7K | 4 | 1.0% |
| 13 | MEPRO PHARMACEUTICALS PRIVATE LIMITED TERBINAFINA VIATRIS 250 MGTERBINAFINE MYLAN 250MG TERBINAFINE MYLPHARMACEUTICAL PRODUCTS TERBINAFINE CREAM 20GM | $225.0K | 6 | 0.8% |
| 14 | IND-SWIFT LIMITED TERBINAFINA VIATRIS 250 MGTERBINAFINE MYLAN 250MG TERBINAFINE MYLTERBINAFINE MYLAN 250 MG TABLETS (TERBIN | $207.0K | 3 | 0.8% |
| 15 | GALENTIC PHARMA INDIA PVT LTD | $204.2K | 2 | 0.7% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Terbinafine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Warning Letter, June 2019 | Yes, March 2024 | Yes | Not verified | Received WHO GMP approval for Unit IV in March 2024; FDA warning letter issued i |
| Intas Pharmaceuticals Limited | Warning Letter, December | Yes, April 2007 | Yes | Not verified | Received EU GMP certification in April 2007; FDA warning letter issued in Decemb |
| Alembic Pharmaceuticals Limited | Approved | Yes | Yes | Multiple approvals between 2024 and 2025 | Received multiple FDA approvals between 2024 and 2025; holds WHO GMP and EU GMP |
TransData Nexus reviewed the regulatory standing of 3 leading Terbinafine exporters from India. 1 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 3 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Terbinafine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," hosts over 800 pharmaceutical companies, including major players like Dr. Reddy's Laboratories, Aurobindo Pharma, and Divi's Laboratories. The city is renowned for its production of Active Pharmaceutical Ingredients (APIs), vaccines, biologics, and biosimilars. The presence of Genome Valley, India's first biotech cluster, along with institutions like the National Institute of Pharmaceutical Education and Research (NIPER) and the Indian Institute of Chemical Technology (IICT), provides a robust R&D infrastructure and a skilled talent pool.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant pharmaceutical manufacturing cluster, contributing nearly 28% of India's pharma production. This region is home to companies such as Zydus, Intas, Torrent, and Cadila Pharmaceuticals. The area boasts a mature pharma ecosystem with strong support infrastructure, including ports, roads, power, and water, facilitating efficient production and distribution of pharmaceutical formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a crucial export gateway for India's pharmaceutical industry. With 929 pharmaceutical units, Maharashtra is a major hub for pharmaceutical manufacturing. The region's strategic location, coupled with well-developed infrastructure and proximity to major ports, enables efficient export operations.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in the Solan district of Himachal Pradesh, is India's largest pharmaceutical manufacturing hub by volume, housing over 1,000 pharma manufacturing units. The region's growth has been driven by favorable government policies, including tax incentives, world-class infrastructure, and proximity to key markets. Baddi's dominance in pharmaceutical manufacturing has significantly contributed to India's position as a global leader in medicine exports.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with supplier concentration, consider engaging with multiple suppliers across different pharmaceutical clusters, such as Hyderabad, Ahmedabad-Vadodara, Mumbai-Thane-Raigad, and Baddi-Nalagarh.
- Evaluate Supplier Capabilities: Assess potential suppliers' manufacturing capabilities, quality assurance processes, and regulatory compliance to ensure they meet international standards.
- Leverage Regional Strengths: Utilize the specific strengths of each pharmaceutical cluster. For instance, source APIs from Hyderabad, formulations from Ahmedabad-Vadodara, and leverage Mumbai-Thane-Raigad for export operations.
- Monitor Regulatory Changes: Stay informed about changes in government policies, tax incentives, and regulatory requirements in different regions to optimize sourcing strategies and maintain compliance.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Terbinafine exporters from India
Aurobindo Pharma Limited — Aurobindo Pharma acquires Khandelwal Labs' non-oncology business
Aurobindo Pharma, through its wholly owned subsidiary Auro Pharma Limited, acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories Pvt Ltd for ₹325 crore. The acquisition includes 23 established brands across 67 stock-keeping units (SKUs) and nine pipeline products in pain management and anti-infective segments. - IMPACT: This acquisition is expected to enhance Aurobindo Pharma's domestic market presence, potentially increasing its Terbinafine exports.
Impact: This acquisition is expected to enhance Aurobindo Pharma's domestic market presence, potentially increasing its Terbinafine exports.
Aurobindo Pharma Limited — Aurobindo Pharma collaborates with global firm for respiratory products
Aurobindo Pharma's subsidiary, Aurobindo Pharma USA Inc., entered into a collaboration and license agreement with a global pharmaceutical company to develop and commercialize specific products in the respiratory therapeutic area. The agreement includes a cost-sharing arrangement, with Aurobindo contributing up to $90 million over the development period. - IMPACT: While focused on respiratory products, this collaboration may indirectly influence Aurobindo's overall export capabilities, including Terbinafine.
Impact: While focused on respiratory products, this collaboration may indirectly influence Aurobindo's overall export capabilities, including Terbinafine.
Aurobindo Pharma Limited — Aurobindo Pharma acquires 51% stake in GLS Pharma
Aurobindo Pharma's board approved the acquisition of a 51% equity stake in GLS Pharma Limited, an oncology-focused company with a manufacturing facility in Hyderabad, for ₹28.05 crore. - IMPACT: This acquisition strengthens Aurobindo's oncology portfolio, potentially affecting its resource allocation and focus on Terbinafine exports.
Impact: This acquisition strengthens Aurobindo's oncology portfolio, potentially affecting its resource allocation and focus on Terbinafine exports.
Common Questions — Terbinafine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which terbinafine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, AUROBINDO PHARMA LTD leads with 302 recorded shipments worth $10.2M. AUROBINDO PHARMA LIMITED (50 shipments) and BAFNA PHARMACEUTICALS LIMITED (10 shipments) are also established high-volume exporters.
Q How many terbinafine manufacturers are there in India?
India has 292 active terbinafine exporters with a combined export market of $27.4M across 3,118 shipments to 121 countries. The top 5 suppliers hold 65.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for terbinafine from India?
Average FOB unit price: $2.72 per unit, ranging from $0.01 to $110.70. Average shipment value: $8.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 292 verified Indian exporters of Terbinafine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,118 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 121 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,118 Verified Shipments
292 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists